The Guam Memorial Hospital Authority said its acquisition of its first-ever intra-aortic balloon pump is a significant advancement that will transform cardiac care on the island. The state-of-the ...

Cardiology experts from UCSF Health presented new research and clinical findings at the American College of Cardiology’s (ACC) 74th Annual Scientific Session and Expo in Chicago, March 29-31.

Subjects with severe aortic stenosis who underwent treatment with either the Evolut TAVR or surgery exhibited “comparable” rates of all-cause death or disabling stroke over five years ...

system in low-risk aortic stenosis individuals. According to the company, the system exhibited “durable” clinical results and “strong” valve performance during the study. The multi-centre, ...

Without treatment, 1 in 10 patients experiencing symptoms of severe aortic stenosis (AS) may die within five weeks. However, the symptoms of severe AS can be difficult to detect and may progress ...

"We also saw a significant improvement in quality of life." While TAVR is now common in patients with aortic stenosis, a type of valvular disease in which the valve becomes narrowed, artificial ...

"Results at five years support Evolut's supra-annular, self-expanding TAVR as a safe, effective, and durable alternative to surgery for patients with severe aortic stenosis, regardless of their ...

Background: Symptomatic severe aortic stenosis (AS) remains undertreated with high resultant mortality despite increased growth and availability of aortic valve replacement (AVR) since the advent of ...

We randomly assigned 7635 participants with aortic stenosis in a 1:1 ratio to undergo TAVI with a CEP device (CEP group) or TAVI without a CEP device (control group). The primary outcome was ...